Equities Analysts Set Expectations for Natus Medical Incorporated’s Q4 2018 Earnings (BABY)
Natus Medical Incorporated (NASDAQ:BABY) – Equities researchers at William Blair issued their Q4 2018 earnings per share (EPS) estimates for shares of Natus Medical in a research report issued on Monday. William Blair analyst B. Weinstein expects that the medical equipment provider will post earnings of $0.65 per share for the quarter.
Several other analysts also recently weighed in on BABY. BidaskClub downgraded Natus Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research upgraded Natus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $44.50.
COPYRIGHT VIOLATION NOTICE: “Equities Analysts Set Expectations for Natus Medical Incorporated’s Q4 2018 Earnings (BABY)” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/09/15/equities-analysts-set-expectations-for-natus-medical-incorporateds-q4-2018-earnings-baby.html.
Natus Medical (NASDAQ BABY) traded down 1.194% on Wednesday, hitting $35.175. The stock had a trading volume of 144,071 shares. The company has a 50 day moving average price of $33.97 and a 200-day moving average price of $36.12. The company has a market cap of $1.14 billion, a price-to-earnings ratio of 60.962 and a beta of 0.96. Natus Medical has a 52-week low of $31.65 and a 52-week high of $44.39.
Natus Medical (NASDAQ:BABY) last posted its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The company had revenue of $122.20 million for the quarter, compared to the consensus estimate of $121.99 million. During the same quarter in the prior year, the company earned $0.39 earnings per share. Natus Medical’s revenue was up 27.3% on a year-over-year basis.
Several hedge funds have recently modified their holdings of the company. Broadfin Capital LLC acquired a new position in shares of Natus Medical in the 2nd quarter valued at about $4,159,000. Koch Industries Inc. lifted its holdings in shares of Natus Medical by 7,423.5% in the 2nd quarter. Koch Industries Inc. now owns 462,472 shares of the medical equipment provider’s stock valued at $450,000 after buying an additional 456,325 shares during the period. Piedmont Investment Advisors LLC lifted its holdings in shares of Natus Medical by 35.4% in the 2nd quarter. Piedmont Investment Advisors LLC now owns 55,540 shares of the medical equipment provider’s stock valued at $2,072,000 after buying an additional 14,508 shares during the period. Daruma Capital Management LLC lifted its holdings in shares of Natus Medical by 13.1% in the 2nd quarter. Daruma Capital Management LLC now owns 1,470,839 shares of the medical equipment provider’s stock valued at $54,862,000 after buying an additional 169,890 shares during the period. Finally, State Street Corp lifted its holdings in shares of Natus Medical by 5.7% in the 2nd quarter. State Street Corp now owns 856,576 shares of the medical equipment provider’s stock valued at $31,946,000 after buying an additional 45,918 shares during the period. 92.65% of the stock is owned by institutional investors and hedge funds.
In other news, Director William M. Moore sold 3,000 shares of the business’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $34.10, for a total value of $102,300.00. Following the completion of the transaction, the director now owns 30,410 shares of the company’s stock, valued at approximately $1,036,981. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 5.50% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.